Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton depression rating scale measures and 18fluorodeoxyglucose (FDG) positron emission tomography (PET).
Seong-Jang KimMin-Young ParkKyoungjune PakJun Hee HanGun-Wook KimHoon-Soo KimHyun-Chang KoMoon-Bum KimByung-Soo KimPublished in: The Journal of dermatological treatment (2018)
Patients with moderate-to-severe psoriasis are at an increased risk for depressive symptoms, and treatment with ustekinumab may be beneficial. FDG-PET does not reflect the changes in depressive symptoms in such patients.
Keyphrases
- positron emission tomography
- depressive symptoms
- computed tomography
- pet ct
- social support
- pet imaging
- sleep quality
- end stage renal disease
- newly diagnosed
- ejection fraction
- early onset
- high intensity
- chronic kidney disease
- clinical trial
- prognostic factors
- physical activity
- drug induced
- psychometric properties
- patient reported